Home > Cardiology > ACC 2019 > Vascular Medicine > Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry

Similar rates of stroke/SE associated with DOAC vs warfarin use in obese non-valvular AF patients: Results from an observational registry

Expert
Dr Steven Deitelzweig, Ochsner Health System, USA
Conference
ACC 2019

The retrospective study of obese non-valvular atrial fibrillation (AF) patients who initiated apixaban, dabigatran, rivaroxaban, or warfarin between January 2013 and September 2015 showed that there is no difference between these DOACs with regard to stroke/systemic embolism (SE) rates when compared with warfarin [11]. Apixaban had a lower rate of major bleeding but it was not significantly different for dabigatran or rivaroxaban in comparison to warfarin.

These results, presented by Dr Steven Deitelzweig (Ochsner Health System, USA), were derived from the ARISTOPHANES population and pooled CMS Medicare data with 4 US commercial claims databases. This covers >180 million beneficiaries annually (approximately 56% of the US population). A total of 62,143 obese patients (19.3 %) with non-valvular AF were included: 13,130 (21.1%) on apixaban, 5,349 (8.6%) on dabigatran, 20,278 (32.6%) on rivaroxaban, and 23,386 (37.6%) on warfarin. Propensity score matching...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on